Emerging molecular targeted therapies in squamous cell carcinoma of the head and neck

Jill Gilbert, Athanassios Argiris

Research output: Contribution to journalReview article

2 Scopus citations

Abstract

In recent years, several therapeutic advances have been made in squamous cell carcinoma of the head and neck (SCCHN). However, despite multimodality therapy, patients with locally advanced SCCHN continue to demonstrate suboptimal 5-year survival rates. The addition of novel, targeted agents to traditional therapies holds promise for clinical benefit. This review will focus on new agents that are promising and their potential role in the treatment of SCCHN.

Original languageEnglish (US)
Pages (from-to)611-619
Number of pages9
JournalClinical Advances in Hematology and Oncology
Volume4
Issue number8
StatePublished - Aug 1 2006
Externally publishedYes

Keywords

  • COX-2
  • EGFR
  • Head and neck cancer
  • Sorafenib
  • VEGF

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Emerging molecular targeted therapies in squamous cell carcinoma of the head and neck'. Together they form a unique fingerprint.

  • Cite this